A Liverpool nurse's long struggle with relentless heartburn ended in a diagnosis of signet ring cell adenocarcinoma, major surgery and a look at rising cases in younger adults
For more than a year and a half a 31-year-old nurse from Liverpool battled recurring, debilitating heartburn that could last for days. Initial consultations led to prescriptions for over-the-counter acid remedies rather than in-person examinations, and temporary relief came from avoiding common dietary triggers.
When symptoms intensified in December 2026, accompanied by stomach and back pain, she paused a recently started weight-loss injection and sought urgent care. At her request clinicians performed an endoscopy — a procedure where a camera inspects the stomach — and were initially reassured the problem was an infection and prescribed antibiotics.
Despite treatment, her condition deteriorated. Repeated visits and a referral request to a bowel specialist were met with suggestions that anxiety might explain ongoing symptoms. It took a routine follow-up endoscopy, performed about 18 months after the symptoms began, to reveal the true cause.
The delayed diagnosis underlines how persistent reflux and new, unexplained abdominal pain can sometimes mask more serious disease and why repeated evaluation is important when symptoms fail to improve.
From symptoms to diagnosis
The follow-up investigation identified a rare and aggressive form of cancer known as signet ring cell adenocarcinoma. This subtype is named because the malignant cells resemble little signet rings under the microscope; unlike many tumours it can grow in a diffuse pattern that makes it harder to detect on imaging. In this case the cancer was fortunately caught before obvious spread, allowing an aggressive treatment plan to begin straightaway. The patient has said that her medical experience helped her to push for the right tests, which likely contributed to detecting the disease at an operable stage.
Treatment and recovery
Treatment started immediately with a course of systemic chemotherapy followed by a radical surgical procedure: a seven-hour total gastrectomy. A gastrectomy is the complete removal of the stomach, and in her case it was recommended because removing the organ offered the best chance to eliminate the tumour. After surgery she spent three days in intensive care and then began a prolonged rehabilitation phase, which included learning how to eat and manage nutrition without a stomach. She underwent four rounds of chemotherapy in total and is now reported to be cancer-free while receiving regular surveillance checks.
Understanding the prognosis
Although she is currently in remission, the outlook for signet ring cell adenocarcinoma can be guarded. Overall five-year survival for this subtype is around 37%, and for patients diagnosed at stage four the figure falls to roughly 7%. These numbers emphasize why early detection matters. Clinicians and charities have also noted a worrying trend: since the 2010s stomach cancer diagnoses have slowly increased among people under 50, by about one percent per year on average, and rates in women appear to be rising at about three percent annually.
Causes, prevention and new treatments
Researchers point to several possible contributors to this shift, including the common stomach bacterium H. pylori. Helicobacter pylori is carried by an estimated 40 percent of people worldwide and can cause ulcers, chronic indigestion and inflammation; when left untreated it is believed to raise the risk of gastric malignancy. Public-health experts recommend testing and treating persistent or unexplained gastric symptoms, especially when accompanied by weight loss, difficulty swallowing or ongoing abdominal pain.
Recent therapeutic advances
In treatment news, the health technology authority in the UK recently approved the immunotherapy drug durvalumab (brand name Imfinzi) for use around the time of surgery in adults with resectable stomach cancer. Immunotherapy works by boosting the immune system’s ability to recognise and attack cancer cells. Trials combining durvalumab with chemotherapy in the perioperative setting showed improved times before disease progression and better survival outcomes compared with chemotherapy alone. Oncologists have described the approval as a meaningful advance for patients facing recurrence risks even after surgery and chemo.
The patient welcomed this development, saying she could not know whether the drug would have helped her personally but that measures which reduce the chance of recurrence are incredibly important. Clinicians advise that anyone with persistent or worsening reflux, new abdominal or back pain, unexplained weight loss or difficulty swallowing should press for further investigation rather than accepting repeated short-term symptom management. Early attention and appropriate testing remain the most effective tools for improving outcomes.
